Background: The objective of this study was to derive and validate a prognostic nomogram to
INTRODUCTION
Perihilar cholangiocarcinoma (PHC) is the most common malignancy of the biliary tree, with an annual incidence in the United States of one to two per 100,000.
1 PHC arises at or near the confluence of the right and left hepatic duct. Bile duct obstruction at the confluence causes painless jaundice and intrahepatic biliary dilatation on imaging. The majority of patients are not candidates for surgical resection because of locally advanced or metastatic disease at the time of presentation. 2 Patients who can undergo a curative-intent resection have an associated median overall survival (OS) that varies from 19 to 39 months. 3 Prognostic factors after resection of PHC have been identified, but prediction of long-term survival for individual patients remains inaccurate. The sixth and seventh editions of the AJCC staging systems for PHC were recently compared and found to both have modest prognostic accuracy. 4 Independent prognostic factors other than T-stage, N-stage, and M-stage have been identified, such as a positive resection margin, moderate or poor tumor differentiation, perineural invasion, and papillary tumors. [5] [6] [7] [8] [9] When positive lymph nodes are not found, evaluation of less than four lymph nodes can cause understaging and is consequently an independent poor prognostic factor. 10 In patients with a negative resection margin, a close or narrow resection margin was also found to be an independent poor prognostic factor. 11 Combining these variables in a prognostic model may further improve survival predictions for individual patients after curative intent resection of PHC.
More accurate predictions for individual patients may improve identification of a high-risk group that may benefit from adjuvant treatment. Moreover, a better prognostic model will allow adequate stratification of patients in randomized controlled trials evaluating adjuvant treatments and enable adjustment for confounding factors when comparing outcomes across centers. Such a prognostic model has been developed for most other cancers, recently including intrahepatic cholangiocarcinoma. 12 The objective of this study was to derive and validate a prognostic nomogram to predict disease specific survival (DSS) for patients who recovered from a curative intent resection of PHC in two independent large institutional cohorts.
METHODS

Patients
Two independent prospectively maintained databases were used, both including consecutive patients who underwent a curative intent resection for PHC. The patient series of Memorial Sloan
Kettering Cancer Center (MSKCC, New York, United States) was used for development of the prognostic model; the patient series of the Academic Medical Center (AMC, Amsterdam, The Netherlands) was used for external validation. Patients were included from 1991 to 2012. All patients had a diagnosis of PHC confirmed at pathologic assessment of the resected specimen. Patients were included with tumors arising from the biliary confluence, right or left hepatic duct, or common hepatic duct. Patients with carcinoma in situ were included because death due to recurrence or long-term complications of treatment was also observed in this subgroup. Patients with 90-day postoperative mortality were excluded since the objective of the prognostic model was to inform patients and physicians about individual cancer-specific prognosis after recovery from surgery.
Patient selection for resection and perioperative management were similar between the two institutions. The main difference in treatment between centers was that all patients in AMC underwent preoperative radiation therapy with three fractions of 3.5 Gy in an effort to reduce postoperative seeding metastases. 13 Adjuvant chemotherapy was not offered in the AMC because it was not reimbursed by Dutch health insurance; in MSKCC it was discretionary and discussed with the patient. Adjuvant therapy was defined as any chemotherapy or radiotherapy that was started within 3 months after surgery. The institutional review board (IRB) at both institutions approved this study.
Variables
Both databases included data on patient demographics, symptoms at presentation, co-morbidities, laboratory test results, cross-sectional imaging, preoperative biliary drainage, type of surgical resection, and pathology of the resected specimen. Evaluation of less than four lymph nodes can cause understaging of lymph node-negative patients, and was previously found to be an independent poor prognostic factor. 10, 14, 15 Lymph node status was therefore divided into three groups: positive, negative with less than four lymph nodes evaluated, and negative with four or more nodes evaluated.
Resection margin was also divided into three groups: a wide, narrow, or positive resection margin.
A wide margin was defined as no adenocarcinoma present at both the specimen margin and any additional bile duct margins. A narrow margin was defined as the presence of adenocarcinoma at the specimen margin with a negative additional bile duct margin. A positive margin was defined as the presence of adenocarcinoma at both the specimen margin and any additional bile duct margins. 11 Preoperative tumor markers (CA 19-9 and CEA) were not considered because of missing values in the majority of patients.
Survival was measured from the date of surgery to the date of death. Patients were censored when alive at the date of last contact. The primary outcome measure was DSS.
Statistical analysis
Statistical analyses were performed using SPSS (Statistical Package for the Social Sciences), version 
11
A nomogram was produced to make patient-specific predictions. The predictive ability of the model was first assessed using concordance probabilities (c-statistic). The concordance probability is the chance that for any two patients, the one with the longer observed DSS also has a longer predicted DSS. Next, model calibration was checked on the derivation and external validation cohort. Patients were stratified in four quartiles based on their nomogram score. Predicted and observed (KaplanMeier estimated) DSS were compared for each quartile. Comparison with the AJCC staging system was performed using concordance probabilities.
RESULTS
Patients and variables
The derivation cohort (MSKCC) consisted of 173 consecutive eligible patients who had a resection of PHC. The validation cohort (AMC) consisted of 133 consecutive eligible patients. Table 1 compares patient characteristics and treatments of the two cohorts. Patients in the derivation cohort were on average 3 years older, were more frequently operated on in the 1991-2001 period (50% versus 33%), had a higher preoperative bilirubin (3.9 versus 1.1 mg/dL), were more likely to undergo preoperative percutaneous biliary drainage without endoscopic drainage (17% versus 4%) or an extended right hepatectomy (33% versus 24%), and less likely to undergo a caudate resection (34% versus 57%). In the derivation cohort 24 patients (14%) received adjuvant chemotherapy and 25 patients (14%) adjuvant radiotherapy; none of the patients in the validation cohort received adjuvant chemotherapy or radiotherapy.
Survival outcomes
The median OS in the study cohort (n=306) was 40 months; the median DSS was 41 months.
Estimated OS at 5 years was 35% and at 10 years 17%. DSS at 5 years was 38% and at 10 years 21%. At last follow-up, 213 patients (70%) had died; only 18 patients (8% of all deaths) had died from causes other than PHC or complications of its management. Median follow-up for patients alive at last follow-up was 48 months. The median DSS differed between the cohorts: 38 months in the derivation and 49 months in the validation cohort (p=0.02). Table 2 presents the results of univariable and multivariable analysis in the derivation cohort (MSKCC, n=173). Lymph node involvement, resection margin status, and tumor differentiation were the only statistically significant independent prognostic factors in the derivation cohort. Adjuvant chemotherapy and radiotherapy were strong poor prognostic factors; however, this association disappeared after adjusting for margin status and lymph node status. None of the covariates in Table   1 that differed between the cohorts was a statistically significant independent prognostic factor.
Univariable and multivariable analysis
Uni-and multivariable analyses in the validation cohort were similar to the derivation cohort (results not shown here). The National Comprehensive Cancer Network (NCCN) guideline recommends consideration of adjuvant treatment after resection of PHC, in particular for patients with a positive resection margin or nodal disease. 16 While the benefit of systemic chemotherapy with gemcitabine and cisplatin was demonstrated in the palliative setting, no randomized controlled trial has been reported in the adjuvant setting. 17 The NCCN recommendation is based on a meta-analysis for adjuvant treatment of patients with any biliary cancer, including retrospective series and only one randomized controlled Draw a vertical line for each prognostic factor (Margin, Nodes, Differentiation) from its appropriate value (e.g., for Margin the values are "Wide", "Narrow", and "Positive") to the axis termed "Points" at the top of the figure. The points assigned for the value of each prognostic factor can be read where the vertical line crosses the "Points" axis. Add the three point scores determined at step 1 and find the sum score on the axis termed "Total Points". Determine the predicted 3-year and 5-year DSS by drawing a vertical line from the sum score on the axis termed "Total Points" down to the 3-year and 5-year DSS axes. The predicted 3-year DSS can be read where the vertical line crosses with the axis termed "3-year DSS".
trial for gallbladder cancer. 18 The greatest benefit was found for margin-positive patients with an The multivariable analysis in the derivation cohort of this study confirmed the prognostic factors known from the literature. [7] [8] [9] [10] [11] However, perineural invasion and papillary tumors were strong prognostic factors in the derivation cohort, but not independent prognostic factors due to correlation with other factors.
The only published prognostic model for PHC is a risk score based on 96 patients and calculated
with age, T-stage, margin status, and adjuvant chemoradiation. 19 Two prognostic models have been developed for extrahepatic cholangiocarcinoma, which included both patients with perihilar and distal cholangiocarcinoma. The first model was based on the same prognostic factors as this study, although the number of evaluated lymph nodes and the difference between a wide and narrow margin were not accounted for. This model had a lower concordance index of 0.67. 20 The second model for extrahepatic cholangiocarcinoma was based on sex, age, tumor differentiation, lymph node status, perineural invasion, and tumor location and had a considerably worse concordance index of 0.63. 21 These three previously published prognostic models have not been externally validated. The Bismuth classification 22 and Blumgart staging 2 both aim to predict resectability rather than survival.
This study has several limitations. Firstly, the calibration was suboptimal in the validation cohort, while the discrimination was good. A suboptimal calibration is common with external model validation due to differences in patient and tumor characteristics as well as management. In a literature review of patients undergoing curative intent surgery for PHC, the median OS ranged from 19 to 39 months across series with more than 100 patients. 3 In light of this wide range in OS, it is less surprising to find a difference of 11 months in median DSS between the derivation and validation cohort. A statistically non-significant difference in patients with positive lymph nodes (29% in derivation and 21%
in validation cohort) may explain the difference in OS to some extent. Another explanation is that in the validation cohort the majority of patients were operated in the more recent period, although the year of surgery was not a prognostic factor. Finally, preoperative radiation in the validation cohort could also have contributed to a difference in OS although evidence for the benefit of radiation is lacking. 13 A second limitation involves the sample size of both cohorts. While the sample size in this study was comparable to nomograms for other less common cancers, 23 ,24 a larger sample size may have further improved this model. However, no other Western single center series of resected PHC with more than 100 patients has been published. 3 Thirdly, about 40% of patients in both cohorts had less than four lymph nodes evaluated. These patients were potentially understaged because insufficient nodes were sampled to rule out nodal metastasis. Collecting at least four lymph nodes has been recommended, because node-negative patients had a worse prognosis if less than four lymph nodes were evaluated.
14 However, while lymphadenectomy is a standard part of the procedure, most series still have a high percentage of patients with less than four lymph nodes evaluated. This limitation has been largely resolved by including the number of evaluated lymph nodes in the nomogram. Fourthly, while the tumor marker CA19-9 is a known prognostic factor for patients with PHC, it could not be evaluated in the current study because of missing values in most patients. 25 Prospective studies should evaluate CA 19-9 and specify whether it was measured before or after adequate biliary drainage. Fifthly, patients were included in both cohorts over a long period spanning two decades. Although some changes in management have occurred over time, the year of resection was not a prognostic factor.
In conclusion, the proposed nomogram predicts DSS after curative intent resection of PHC based on lymph node involvement and count, resection margin involvement including additional margins, and tumor differentiation. The concordance index was good in both the derivation and the validation cohorts and clearly better than the AJCC staging. However, calibration was suboptimal because DSS differed between the two institutions. The nomogram can be used to inform patients after curative intent resection of PHC, guide adjuvant treatment decisions, and stratify patients in future adjuvant randomized controlled trials.
